All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On December 18, 2017, Natalie Dimier of Basel, Switzerland and colleagues published online in Blood, a meta-analysis of three randomized, phase III clinical trials. The objective was to evaluate minimal residual disease (MRD) at the end of induction treatment with chemo-immunotherapy as a surrogate endpoint for progression-free survival (PFS) in chronic lymphocytic leukemia (CLL). Data were collected from three, phase III clinical trials (NCT00281918, NCT00769522, NCT01010061).
This analysis was done to determine whether the treatment effect on MRD response in PB at the end of induction treatment with chemo-immunotherapy can predict treatment effect on PFS in patients with CLL. To this end, the investigators employed PB- MRD data from three randomized, phase 3 trials to determine the relative strength between treatment effects using a meta-regression model. To this end, this meta-analysis demonstrated a statistically significant relationship between treatment effects on PFS and MRD. This model gives credence to the use of MRD as a primary endpoint in CLL chemo-immunotherapy clinical trials.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox